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Discussion
In recent years, the number of patients meeting the criteria for
implantation of an ICD has increased dramatically. A number of
creative implantation methods have been reported, but each is
faced with its own set of potential complications.1-3 These com-
plications range from postpericardiotomy syndrome4 to lead or
patch trauma and failure.5
There are a number of advantages to this implantation, the first
of which is that the patient avoids a median sternotomy, and the
second of which is that no subcutaneous array is required, there-
fore eliminating the possibility of array failure.
This case is evidence that a minimally invasive approach to
pediatric ICD implantation can be successful. In a patient deter-
mined to be too small for traditional transvenous implantation or
with a lack of venous access, this method of ICD implantation
should be considered.
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Heparin-induced thrombocytopenia (HIT) is a severethrombogenic disease requiring the use of alternativeanticoagulants. Argatroban is a synthetic monovalentdirect thrombin inhibitor indicated for prophylaxis
and treatment of thrombosis in patients with HIT. Renal failure
requiring renal replacement therapy (RRT) is a frequent compli-
cation in patients in whom HIT develops after cardiovascular
surgery. The hepatic metabolism and relative short elimination
half-life of 45 minutes render argatroban an interesting option for
anticoagulation during RRT. However, there are scant data on
dosing, pharmacokinetics, safety, and efficacy of argatroban in this
indication. We report our initial experience with argatroban anti-
coagulation for continuous veno-venous hemofiltration (CVVH)
and intermittent hemodialysis (IHD) in 10 patients diagnosed with
HIT after cardiovascular surgery in whom acute renal failure
developed necessitating RRT.
Patients and Methods
After approval by the local ethics committee and having obtained
informed consent, we analyzed the data of 10 patients. In accor-
dance with the study protocol, data were collected for a maximum
of 30 days during RRT. Clinical follow-up of patient outcome was
performed for 3 months after initiation of RRT with argatroban.
All patients had thrombocytopenia after surgery or presented per-
sistent thrombocytopenia postoperatively. In all patients the diag-
nosis of HIT was confirmed in an antibody assay (Particle Gel
Immune Assay; DiaMed, Cressier sur Morat, Switzerland) and in
the heparin-induced platelet aggregation assay. The decision to
perform CVVH (Ultraflux AV 600S; polysulfone high flux hemo-
dialyzer, Fresenius Medical Care AG, Bad Homburg, Germany) or
IHD (Polyflux 140 H; polyamix high flux hemodialyzer, Gambro,
Hechingen, Germany) was based on stability of hemodynamics
and mobility of the patient. In general, RRT was started with
CVVH and changed to IHD after hemodynamics were stable and
patient mobility increased. Only in 1 patient was RRT initiated
with IHD. Target activated partial thromboplastin time (aPTT)
(Roche Diagnostics, Mannheim, Germany, normal value 20-22
seconds) during RRT was 50 to 80 seconds and 40 to 60 seconds
in periods without CVVD or IHD. Before the start of RRT,
argatroban administration was started with a continuous infusion
of 1 g · kg1 · min1 for 1 hour. Thereafter, the aPTT was
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measured and RRT started. During the procedures, argatroban
infusion rates were adjusted to target values in increments of 0.25
g · kg1 · min1 depending on the results of coagulation tests.
Results
There were 7 male and 3 female patients. The mean age was 58.8 
11.0 years. Surgery performed was implantation of a ventricular
assist device in 2 patients, heart transplantations in 3, lung trans-
plantation in 1, pulmonary artery thrombectomy in 1, replacement
of a thoracoabdominal aortic aneurysm in 1, and coronary artery
bypass grafting in 2. No bleeding events attributed to problems of
anticoagulation were observed. Five patients died during the ob-
servation period. Data for argatroban dosing and aPTT values are
presented in Table 1. The total duration of the 73 CVVH proce-
dures was 2252 hours with a mean of 30.8  27.1 hours. The total
duration of the 29 IHD procedures was 160 hours with a mean of
3.9  1.0 hours. No filter system had to be exchanged during IHD
as a result of premature filter thrombosis.
Discussion
This is the first investigation providing a dosing regimen for the
use of argatroban during RRT in patients with HIT after cardio-
vascular surgery. Our data provide convincing evidence that in
these patients the current protocol provides safe and effective
anticoagulation for CVVH and IHD. The data obtained suggest the
following:
1. In view of the good patency of filters of approximately 30
hours and the low rate of bleeding complications, prolon-
gation of the aPTT to the 3- to 4-fold appears to be safe and
effective for argatroban anticoagulation for both CVVH and
IHD in this patient population.
2. In a previous investigation, we1 demonstrated that argatro-
ban dosing in patients after cardiovascular surgery is con-
siderably lower than in medical patients and that the anti-
coagulant effect of the drug is immediately achieved by
continuous infusion so that no bolus administration is nec-
essary. In line with these observations, in our patients the
mean argatroban infusion rate during RRT of 0.06 to 0.12
g · kg1 · min1 was considerably lower than the median
infusion rate of 1.7 g · kg1 · min1 in medical patients.
Moreover, a starting infusion rate of 1 g · kg1 · min1 for
1 hour provided reliable anticoagulation for the initiation of
RRT, so that no bolus administration was necessary.2
3. In contrast to observations with the other direct thrombin
inhibitors, bivalirudin and lepirudin, and in line with pre-
vious observations, the fact that argatroban dosing during
and after CVVH and IHD was almost comparable with
dosing during intervals without RRT suggests only minor
elimination of the drug via the filter system.3-5 However,
elimination of argatroban appears to be slightly more pro-
nounced during CVVH.
On the basis of these observations, we conclude that dosing of
argatroban according to the protocol outlined here provides reli-
able, safe, and effective anticoagulation during CVVH and IHD in
patients with HIT after cardiovascular surgery. Inasmuch as the
argatroban elimination half-life of 45 minutes is relatively short,
elimination is independent of renal function and, as we observed,
extracorporeal elimination during both CVVH and IHD is clini-
cally insignificant, so that no dose adjustment is necessary during
RRT, argatroban anticoagulation appears to be an excellent option
in this indication. However, further detailed studies are needed to
confirm this assumption.
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TABLE 1. Argatroban dose and aPTT during and between CVVH and IHD
During CVVH
(n  9)
Between CVVH procedures
(n  9)
Before IHD
(n  6)
During IHD
(n  6)
After IHD
(n  6)
Between IHD procedures
(n  6)
No. of procedures 73 29
Argatroban
(g · kg1 · min1)
0.13 0.21 0.29 0.31 0.07 0.11 0.06 0.11 0.07 0.12 0.20 0.20
aPTT 64.4  12.9 64.8 17.3 53.4 10.6 58.4 9.8 54.0 16.0 57.3 16.2
aPTT, Activated partial thromboplastin time; CVVH, continuous veno-venous hemodialysis; IHD, intermittent hemodialysis.
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